Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Immatics Reports Interim Clinical Data Update On ACTengine IMA203 TCR-T Monotherapy Targeting PRAME

Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients with high and low PRAME expression Update covers data from
byBenzinga Newsdesk
October 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients with high and low PRAME expression
  • Update covers data from 27 patients in completed Phase 1a dose escalation and first 5 patients in Phase 1b dose expansion (cohort A) treated with IMA203 monotherapy
  • Confirmed objective response rate (cORR): 50% (6/12) at target dose or above with at least 1 billion infused TCR-T cells across Phase 1a and 1b; thereof 80% cORR (4/5) in Phase 1b patients alone with all responses ongoing at data cut-off
  • Confirmed responses across different solid tumor types: cutaneous melanoma, ovarian cancer, head and neck cancer, uveal melanoma, and synovial sarcoma
  • Treatment with IMA203 continues to show manageable tolerability; biological data including T cell engraftment, persistence and tumor infiltration consistent with clinical data
  • IMA203 TCR-T is part of Immatics’ strategy to leverage the full clinical potential of targeting PRAME; next data read-outs on IMA203 monotherapy, IMA203 in combination with a checkpoint inhibitor and 2nd generation IMA203CD8 planned during 2023
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

These 5 High-Growth Small-Cap Stocks Surged More Than 100% In Q1: What’s Next?

By Piero Cingari
April 5, 12:15 PM
The S&P 500 index, which is tracked by the SPDR S&P 500 ETF Trust (ARCA: SPY), posted a gain of 6.2% in the first quarter of 2023, while technology stocks in the Nasdaq 100 index, which is tracked by the Invesco QQQ Trust Series 1 (ARCA: QQQ), fared much better by posting a 20% increase in the quarter, also marking the third-best quarterly per

AI